Utilizing Anti-Tumor Immunity Against Breast Cancer : Investigations of Anti-Tumor Immune Cells and Cytokines Escalation and Function Enhancement
Abstract
Breast cancer (BC) is one of the most common cancers in women, and it continues to be a key area of extensive basic and clinical study to understand its complexity. Immune cells significantly impact BC progression, with some promoting antitumor immunity and others facilitating tumor growth. Immunotherapy represents a promising approach to modifying the immune system for BC treatment. Immunotherapy works by enhancing the ability of the immune system to recognize and attack cancer cells. Future therapy utilizing anti-tumor immunity against breast cancer will be necessary to achieve a significant medical remission of the disease. Investigations involved in this review were limited in utilization of monotherapy and polytherapy against breast cancer which has been successful escalating and enhancing the function of CD8+ T lymphocytes, M1 macrophages, Natural Killer cells, and anti-tumor cytokines in pre-clinical and clinical trial. This review summarized recent investigations that reach their purpose of anti-tumor immune cells and cytokines escalation and function enhancement in breast cancer. This review also highlighted various approaches used as treatment in distinct molecular subtypes of breast cancer. In this review we show that utilization of monotherapy and polytherapy against breast cancer has been successful escalating and enhancing the function of anti-tumor immune cells such as CD8+ T lymphocytes, M1 macrophages, Natural Killer cells, and anti-tumor cytokines in pre-clinical and clinical trials. The studies show potential for manipulating the immune system to eradicate the breast tumor and stimulate antitumor immunity.
Keywords: breast cancer, immunotherapy, anti-tumor immunity
Full Text:
PDFReferences
Donovan SM, Abrahams M, Anthony JC, Bao Y, Barragan M, Bermingham KM, et al. Personalized nutrition: perspectives on challenges, opportunities, and guiding principles for data use and fusion. Crit Rev Food Sci Nutr. 2025;65(0):1-18, CrossRef.
Quadri SA, Alshadidi WAF, Huqh MZU, Villuri CSL, Vyas R, Vaddamanu SK. Comparison of the periodontal status between orthodontic aligner treatment and traditional orthodontic treatment: a systematic review and meta-analysis. Int J Dent Hyg. 2026:1-14, CrossRef.
Lucchese A, Bonini C, Noviello M, Lupo Stanghellini MT, Greco R, Peccatori J, et al. The effect of removable orthodontic appliances on oral microbiota: a systematic review. Applied Sciences. 2021;11(6):2881, CrossRef.
Jiang Q, Li J, Mei L, Du J, Levrini L, Abbate GM, et al. Periodontal health during orthodontic treatment with clear aligners and fixed appliances: A meta-analysis. J Am Dent Assoc. 2018;149(8):712-20, CrossRef.
Di Spirito F, D'Ambrosio F, Cannatà D, D'Antò V, Giordano F, Martina S. Impact of Clear Aligners versus Fixed Appliances on Periodontal Status of Patients Undergoing Orthodontic Treatment: A Systematic Review of Systematic Reviews. Healthcare. 2023;6;11(9):1340, CrossRef.
Nemec M, Ringl P, Spettel K, Schneider L, Kriz R, Galazka S, Sedlak M, et al. Exploring the impact of orthodontic appliances on the oral microbiome and inflammatory parameters. Prog Orthod. 2025;7;26(1):13, CrossRef.
Al-Anezi SA, Harradine NW. Quantifying plaque during orthodontic treatment: Angle Orthod. 2012;82(4):748-53, CrossRef.
España-Pamplona P, Bernés-Martínez L, Andrés-Castelló C, Bolás-Colveé B, Adobes-Martín M, Garcovich D. Changes in the oral microbiota with the use of aligners vs. braces: A systematic review. J Clin Med. 2024;6;13(23):7435, CrossRef.
Engström C, Granström G, Thilander B. Effect of orthodontic force on periodontal tissue metabolism. A histologic and biochemical study in normal and hypocalcemic young rats. Am J Orthod Dentofacial Orthop. 1988;93(6):486-95, CrossRef.
Crego-Ruiz M, Jorba-García A. Assessment of the periodontal health status and gingival recession during orthodontic treatment with clear aligners and fixed appliances: A systematic review and meta-analysis. Med Oral Patol Oral Cir Bucal. 2023;28(4):e330-e40, CrossRef.
Brown IS. The effect of orthodontic therapy on certain types of periodontal defects. I. Clinical findings. J Periodontol.1973;44(12):742-56, CrossRef.
Ardila CM, Elorza-Durán A, Arrubla-Escobar D. Efficacy of CAD/CAM technology in interventions implemented in orthodontics: A scoping review of clinical trials. Biomed Res Int. 2022:5310555,
https://doi.org/10.1155/2022/5310555">CrossRef.
Sfondrini MF, Butera A, Di Michele P, Luccisano C, Ottini B, Sangalli E, et al. Microbiological changes during orthodontic aligner therapy: A prospective clinical trial. Applied Sciences. 2021;11(15):6758, CrossRef.
Partouche AJD, Castro F, Baptista AS, Costa LG, Fernandes JCH, Fernandes GVO. Effects of multibracket orthodontic treatment versus clear aligners on periodontal health: an integrative review. Dent J. 2022;10(10):177, CrossRef.
Li Y, Zhan Q, Bao M, Yi J, Li Y. Biomechanical and biological responses of periodontium in orthodontic tooth movement: up-date in a new decade. Int J Oral Sci. 202;13(1):20, CrossRef.
Karkhanechi M, Chow D, Sipkin J, Sherman D, Boylan RJ, Norman RG, et al. Periodontal status of adult patients treated with fixed buccal appliances and removable aligners over one year of active orthodontic therapy. Angle Orthod. 2013;83(1):146-51, CrossRef.
Kredig C, Peuckert E, Schmidtmann I, Drechsler T, Erbe C. Oral health in adolescents: periodontal inflammatory biomarkers during orthodontic clear aligner therapy. Clin Oral Investig. 2025;29(3):168, CrossRef.
Sabouni W, Mercier JP, Brincat A. Integrating Periodontal Care and Orthodontic Treatment: A Case Study of a Patient Treated With Clear Aligner Therapy (CAT). Case Rep Dent. 2026 Mar 3;2026:1903921, CrossRef.
Madariaga ACP, Bucci R, Rongo R, Simeon V, D'Antò V, Valletta R. Impact of fixed orthodontic appliance and clear aligners on the periodontal health: a prospective clinical study. Dent J (Basel). 2020;8(1):4, CrossRef.
Heribanová B, Janáková K, Tomášik J, Tichá D, Harsányi Š, Thurzo A. Current applications and future perspectives of artificial intelligence in face-driven orthodontics: a scoping review. Biomimetics. 2026;11(2):146, CrossRef.
Hussain U, Campobasso A, Noman M, Alam S, Mujeeb R, Shehzad S, et al. Influence of elastomeric and steel ligatures on periodontal health during fixed appliance orthodontic treatment: a systematic review and meta-analysis. Prog Orthod. 2024;25:24,
https://doi.org/10.1186/s40510-024-00520-8">CrossRef.
Xu M, Li G, Tian J, Xie F, Zuo J, Hu J,et al. Comparison of the effects of clear aligners and fixed appliances on the oral microbiota and reactive oxygen species: a prospective study. Front Cell Infect Microbiol. 2026;15:1738047, CrossRef.
Jiang Q, Li J, Mei L, Du J, Levrini L, Abbate GM, et al. Periodontal health during orthodontic treatment with clear aligners and fixed appliances: A meta-analysis. J Am Dent Assoc. 2018;149(8):712-20, CrossRef.
Rossini G, Parrini S, Castroflorio T, Deregibus A, Debernardi CL. Periodontal health during clear aligners treatment: a systematic review. Eur J Orthod. 2015;37(5):539-43. CrossRef.
Liu J, Zhang C, Shan Z. Application of artificial intelligence in orthodontics: current state and future perspectives. Healthcare. 2023;11(20):2760, CrossRef.
Xiong X, Zheng LW, Ding Y, Chen YF, Cai YW, Wang LP, et al. Breast cancer: pathogenesis and treatments. Signal Transduct Target Ther. 2025;10(1):49, CrossRef.
Gatti-Mays ME, Balko JM, Gameiro SR, Bear HD, Prabhakaran S, Fukui J, et al. If we build it they will come: targeting the immune response to breast cancer. NPJ Breast Cancer. 2019;5:37, CrossRef.
Nakasone ES, Hurvitz SA, McCann KE. Harnessing the immune system in the battle against breast cancer. Drugs Context. 2018;7:212520, CrossRef.
Amens JN, Bahçecioglu G, Zorlutuna P. Immune system effects on breast cancer. Cell Mol Bioeng. 2021;14(4):279-92. CrossRef.
Edechi CA, Ikeogu N, Uzonna JE, Myal Y. Regulation of immunity in breast cancer. Cancers. 2019;11(8):1-18, CrossRef.
Said SS, Ibrahim WN. Cancer resistance to immunotherapy: comprehensive insights with future perspectives. Pharmaceutics. 2023;4;15(4):1143, CrossRef.
Anayyat U, Ahad F, Muluh TA, Zaidi SAA, Usmani F, Yang H, et al. Immunotherapy: Constructive Approach for Breast Cancer Treatment. Breast Cancer Targets Ther. 2023;15:925-51, CrossRef.
Debien V, De Caluwé A, Wang X, Piccart-Gebhart M, Tuohy VK, Romano E, et al. Immunotherapy in breast cancer: an overview of current strategies and perspectives. NPJ Breast Cancer. 2023;9(1):7, CrossRef.
Heater NK, Warrior S, Lu J. Current and future immunotherapy for breast cancer. J Hematol Oncol. 2024;17(1):131, CrossRef.
Bondhopadhyay B, Hussain S, Kasherwal V. The differential effect of the immune system in breast cancer. Explor Med. 2023;4:1094-108. CrossRef.
Imani S, Farghadani R, Roozitalab G, Maghsoudloo M, Emadi M, Moradi A, et al. Reprogramming the breast tumor immune microenvironment: cold-to-hot transition for enhanced immunotherapy. J Exp Clin Cancer Res. 2025;44(1):1-51. CrossRef.
Badiu DC, Zgura A, Gales L, Iliescu L, Anghel R, Haineala B. Modulation of immune system - strategy in the treatment of breast cancer. In Vivo. 2021;35(5):2889-94. CrossRef.
Prové A, Dirix L. Neratinib for the treatment of breast cancer. Expert Opin Pharmacother. 2016;17(16):2243-8. CrossRef.
Henriques B, Mendes F, Martins D. Immunotherapy in breast cancer: when, how, and what challenges? Biomedicines. 2021;9(11):1687, CrossRef.
Jallah JK, Dweh TJ, Anjankar A, Palma O. A Review of the Advancements in Targeted Therapies for Breast Cancer. Cureus. 2023;15(10):e47847, CrossRef.
Wang J, Wu SG. Breast cancer: an overview of current therapeutic strategies, challenge, and perspectives. Breast Cancer Targets Ther. 2023;15:721-30, CrossRef.
Burguin A, Diorio C, Durocher F. Breast cancer treatments: updates and new challenges. J Pers Med. 2021;11(8):808, CrossRef.
Yi M, Li T, Niu M, Mei Q, Zhao B, Chu Q, et al. Exploiting innate immunity for cancer immunotherapy. Mol Cancer. 2023;22(1):1-55, CrossRef.
Li SJ, Chen JX, Sun ZJ. Improving antitumor immunity using antiangiogenic agents: Mechanistic insights, current progress, and clinical challenges. Cancer Commun. 2021;41(9):830-50, CrossRef.
Shimizu T, Oba T, Oshi M, Ito K ichi. Eribulin promotes proliferation of CD8+ T cells and potentiates T cell-mediated anti-tumor activity against triple-negative breast cancer cells. Breast Cancer Res Treat. 2024;203(1):57-71, CrossRef.
Zhang Y, Naderi Yeganeh P, Zhang H, Wang SY, Li Z, Gu B, et al. Tumor editing suppresses innate and adaptive antitumor immunity and is reversed by inhibiting DNA methylation. Nat Immunol. 2024;25:1858-70, CrossRef.
Vethencourt A, Trinidad EM, Dorca E, Petit A, Soler-Monsó MT, Ciscar M, et al. Denosumab as an immune modulator in HER2-negative early breast cancer: results of the window-of-opportunity D-BIOMARK clinical trial. Breast Cancer Res. 2025;27(1).68, CrossRef.
Gurrea-Rubio M, Wu Q, Amin MA, Tsou PS, Campbell PL, Amarista CI, et al. Activation of cytotoxic lymphocytes through CD6 enhances killing of cancer cells. Cancer Immunol Immunother. 2024;73(2):1-12, CrossRef.
Wang F, Li W, Han G, Xie J, Bai X. A ROR1 targeted bispecific T cell engager shows high potency in the pre-clinical model of triple negative breast cancer. Breast Cancer Res. 2025;27(1):47, CrossRef.
Herault A, Mak J, de la Cruz-Chuh J, Dillon MA, Ellerman D, Go MA, et al. NKG2D-bispecific enhances NK and CD8+ T cell antitumor immunity. Cancer Immunol Immunother. 2024;73(10):1-16, CrossRef.
Liu B, Huang J, Xiao J, Xu W, Zhang H, Yuan Y, et al. The Streptococcus virulence protein PepO triggers anti-tumor immune responses by reprograming tumor-associated macrophages in a mouse triple negative breast cancer model. Cell Biosci. 2023;13(1):1-19, CrossRef.
Lopes AMM, Vieira JF, da Silva SFM, Murta EFC, Michelin MA. Dendritic cell immunotherapy has its antitumor action improved by the LPS in the maturation process. Clin Transl Oncol. 2025;27(8):3501-10, CrossRef.
Zhu B, Cai Y, Zhou L, Zhao L, Chen J, Shan X, et al. Injectable supramolecular hydrogel co-loading abemaciclib/NLG919 for neoadjuvant immunotherapy of triple-negative breast cancer. Nat Commun. 2025;16(1):687, CrossRef.
Dastouri M, Kilic N, Yilmaz H. The apoptotic effects of NK-92 cells stimulated with an anti-CD226 antibody on MDA-MB-231 triple-negative breast cancer cells. Med Oncol. 2023;40(8):1-11, CrossRef.
Zhao Q, Pramanik J, Lu Y, Homer NZM, Imianowski CJ, Zhang B, et al. Perturbing local steroidogenesis to improve breast cancer immunity. Nat Commun. 2025;16(1): 3945, CrossRef.
Naik A, Thomas R, Al-Khalifa A, Qasem H, Decock J. Immunomodulatory effects of tumor lactate dehydrogenase c (LDHC) in breast cancer. Cell Commun Signal. 2025;23(1):145, CrossRef.
Lasso P, Rojas L, Arévalo C, Urueña C, Murillo N, Nossa P, et al. Piper nigrum extract suppresses tumor growth and enhances the antitumor immune response in murine models of breast cancer and melanoma. Cancer Immunol Immunother. 2023;72(10):3279-92,
https://doi.org/10.1007/s00262-023-03487-3">CrossRef.
Zeng A, Liang X, Zhu S, Liu C, Wang S, Zhang Q, et al. Chlorogenic acid induces apoptosis, inhibits metastasis and improves antitumor immunity in breast cancer via the NF-κB signaling pathway. Oncol Rep. 2021;45(2):717-27, CrossRef.
Nilkhet S, Mongkolpobsin K, Sillapachaiyaporn C, Wongsirojkul N, Tencomnao T, Chuchawankul S. M1 macrophages polarized by crude polysaccharides isolated from Auricularia polytricha exhibit anti-tumor effect on human breast cancer cells. Sci Rep. 2024;14(1):1-13, CrossRef.
Jędrzejewski T, Sobocińska J, Maciejewski B, Spisz P, Walczak-Skierska J, Pomastowski P, et al. In vitro treatment of triple-negative breast cancer cells with an extract from the coriolus versicolor mushroom changes macrophage properties related to tumourigenesis. Immunol Res. 2025;73(1):14, CrossRef.
Liu M, Zheng L, Zhang Y, Tian J. Mechanistic insights into pachymic acid's action on triple-negative breast cancer through TOP2A targeting. Sci Rep. 2025;15(1):2856, CrossRef.
Xia Y, Yang M, Xiao X, Tang W, Deng J, Wu L, et al. Low-intensity pulsed ultrasound activated the anti-tumor immunity by irradiating the spleen of mice in 4 T-1 breast cancer. Cancer Immunol Immunother. 2024;73(3):1-12, CrossRef.
Yu C, Xing H, Fu X, Zhang Y, Yan X, Feng J,et al. Effect and mechanisms of shikonin on breast cancer cells in vitro and in vivo. BMC Complement Med Ther. 2024;24(1):389, CrossRef.
Soll D, Chu CF, Sun S, Lutz V, Arunkumar M, Gachechiladze M, et al. Sodium chloride in the tumor microenvironment enhances T cell metabolic fitness and cytotoxicity. Nat Immunol. 2024;25(10):1830-44, CrossRef.
Boulifa A, Raftery MJ, Franzén AS, Radecke C, Stintzing S, Blohmer JU, et al. Role of beta-(1→3)(1→6)-D-glucan derived from yeast on natural killer (NK) cells and breast cancer cell lines in 2D and 3D cultures. BMC Cancer. 2024;24(1):1-12,
https://doi.org/10.1186/s12885-024-11979-3">CrossRef.
Thepmalee C, Jenkham P, Ramwarungkura B, Suwannasom N, Khoothiam K, Thephinlap C, et al. Enhancing cancer immunotherapy using cordycepin and Cordyceps militaris extract to sensitize cancer cells and modulate immune responses. Sci Rep. 2024;14(1):1-17, CrossRef.
Li X, Su N, Yu H, Li X, Sun SL. Hainanenin-1, an oncolytic peptide, triggers immunogenic cell death via STING activation in triple-negative breast cancer. Cell Commun Signal. 2024;22(1):1-16, CrossRef.
Lee S, Toft NJ, Axelsen T V., Espejo MS, Pedersen TM, Mele M, et al. Carbonic anhydrases reduce the acidity of the tumor microenvironment, promote immune infiltration, decelerate tumor growth, and improve survival in ErbB2/HER2-enriched breast cancer. Breast Cancer Res. 2023;25(1):1-27, CrossRef.
Luo H, Lv J, Wen P, Zhang S, Ma W, Yang Z. Supramolecular polyrotaxane-based nano-theranostics enable cancer-cell stiffening for enhanced T-cell-mediated anticancer immunotherapy. Nat Commun. 2025;16(1):1-13,CrossRef.
Wang R, Li G, Gao F, Xu F, Li X, Zhang J, et al. Ultrasound-responsive spherical nucleic acid against c-Myc/PD-L1 to enhance anti-tumoral macrophages in triple-negative breast cancer progression. Sci China Life Sci. 2024;67(4):698-710, CrossRef.
Sammarco A, Guerra G, Eyme KM, Kennewick K, Qiao Y, Hokayem J El, et al. Targeting SCD triggers lipotoxicity of cancer cells and enhances anti-tumor immunity in breast cancer brain metastasis mouse models. bioRxiv Prepr Serv Biol. 2025;8(1):562, CrossRef.
Miller KD, O'Connor S, Pniewski KA, Kannan T, Acosta R, Mirji G, et al. Acetate acts as a metabolic immunomodulator by bolstering T-cell effector function and potentiating antitumor immunity in breast cancer. Nat Cancer. 2023;4(10):1491-507, CrossRef.
Murtadha AH, Sharudin NA, Azahar IIM, Has ATC, Mokhtar NF. Upregulation of mhc i antigen processing machinery gene expression in breast cancer cells by trichostatin a. Mol Biol. 2023;57(6):1212-27, CrossRef.
Huang W, Zhu Q, Shi Z, Tu Y, Li Q, Zheng W, et al. Dual inhibitors of DNMT and HDAC induce viral mimicry to induce antitumour immunity in breast cancer. Cell Death Discov. 2024;10(1) , CrossRef.
Mo H, Yu Y, Sun X, Ge H, Yu L, Guan X, et al. Metronomic chemotherapy plus anti-PD-1 in metastatic breast cancer: a Bayesian adaptive randomized phase 2 trial. Nat Med. 2024;30:2528-39, CrossRef.
Voorwerk L, Isaeva OI, Horlings HM, Balduzzi S, Chelushkin M, Bakker NAM, et al. PD-L1 blockade in combination with carboplatin as immune induction in metastatic lobular breast cancer: the GELATO trial. Nat Cancer. 2023;4(4):535-49, CrossRef.
Fu C, Ji W, Cui Q, Chen A, Weng H, Lu N, et al. GSDME-mediated pyroptosis promotes anti-tumor immunity of neoadjuvant chemotherapy in breast cancer. Cancer Immunol Immunother. 2024;73(9):1-15, CrossRef.
Ding C, Li Z, Zheng Y, Li K, Yu W, Kong L, et al. Effects of albumin-bound paclitaxel combined with sophora subprostrate polysaccharide on inflammatory factors and immune function in breast cancer rats. Discov Oncol. 2025;16(1):716, CrossRef.
Ye Z, Liang L, Xu Y, Yang J, Li Y. Probiotics influence gut microbiota and tumor immune microenvironment to enhance anti-tumor efficacy of doxorubicin. Probiotics Antimicrob Proteins. 2024;16(2):606-22, CrossRef.
Korkaya H, Koksalar AF, Caglayan A, Alkan H, Benson E, Gunduz Y,et al. Dual activity of minnelide chemosensitize basal/triple negative breast cancer stem cells and reprograms immunosuppressive tumor microenvironment. Res Sq. 2024;14(1):22487, CrossRef.
Hassani E, Mozzendizaji S, Shafiei-Irannejad V, Mohammadzadeh A. Metformin boosts doxorubicin efficacy and increases CD8 + T cell frequency in mouse breast cancer. Clin Transl Oncol. 2024;27(5):2060-6, CrossRef.
Pan F, Liu J, Chen Y, Zhu B, Chen W, Yang Y, et al. Chemotherapy-induced high expression of IL23A enhances efficacy of anti-PD-1 therapy in TNBC by co-activating the PI3K-AKT signaling pathway of CTLs. Sci Rep. 2024;14(1):1-15, CrossRef.
Raninga P V., Zeng B, Moi D, Trethowan E, Saletta F, Venkat P,et al. CBL0137 and NKG2A blockade: a novel immuno-oncology combination therapy for Myc-overexpressing triple-negative breast cancers. Oncogene. 2025;44:893-908, CrossRef.
Zhang J, Zhang G, Zhang W, Bai L, Wang L, Li T, et al. Loss of RBMS1 promotes anti-tumor immunity through enabling PD-L1 checkpoint blockade in triple-negative breast cancer. Cell Death Differ. 2022;29(11):2247-61, CrossRef.
Zheng H, Wu L, Chen J, Na N, Lou G. Neoadjuvant nivolumab plus bevacizumab therapy improves the prognosis of triple-negative breast cancer in humanized mouse models. Breast Cancer. 2024;31(3):371-81, CrossRef.
Kok M. Neoadjuvant nivolumab or nivolumab plus ipilimumab in early-stage triple-negative breast cancer: a phase 2 adaptive trial. Nat Med. 2024;30:3223-35, CrossRef.
Kim J, Kim M, Yong SB, Han H, Kang S, Lahiji SF, et al. Engineering TGF-β inhibitor-encapsulated macrophage-inspired multi-functional nanoparticles for combination cancer immunotherapy. Biomater Res. 2023;27(1):1-16, CrossRef.
Nascimento CS, Carvalho JG, Tavares NC, Lage ACP, Pascoal-Xavier MA, Melo CP de, et al. Polyaniline-coated iron oxide nanoparticles reprogram macrophages and modulate the tumor microenvironment to inhibit breast cancer progression and metastasis. Cancer Nanotechnol. 2025;16(1):1-25, CrossRef.
Shah JR, Dong T, Phung AT, Khan S, Aisagbonhi O, Blair SL, et al. Liposomal oncolytic adenovirus as a neoadjuvant therapy for triple-negative breast cancer. Sci Rep. 2025;15(1):1-18, CrossRef.
Mu Y, Fan Y, He L, Hu N, Xue H, Guan X, et al. Enhanced cancer immunotherapy through synergistic ferroptosis and immune checkpoint blockade using cell membrane-coated nanoparticles. Cancer Nanotechnol. 2023;14(1):1-18, CrossRef.
Hamouda AEI, Filtjens J, Brabants E, Kancheva D, Debraekeleer A, Brughmans J, et al. Intratumoral delivery of lipid nanoparticle-formulated mRNA encoding IL-21, IL-7, and 4-1BBL induces systemic anti-tumor immunity. Nat Commun. 2024;15(1):10635, CrossRef.
Jiang Z, Cai G, Liu H, Liu L, Huang R, Nie X, et al. A combination of a TLR7/8 agonist and an epigenetic inhibitor suppresses triple-negative breast cancer through triggering anti-tumor immune. J Nanobiotechnology. 2024;22(1):1-21, CrossRef.
Wang Y, Drum DL, Sun R, Zhang Y, Chen F, Sun F, et al. Stressed target cancer cells drive nongenetic reprogramming of CAR T cells and solid tumor microenvironment. Nat Commun. 2023;14(1):5727,
Liu CC, Wolf M, Ortego R, Grencewicz D, Sadler T, Eng C. Characterization of immunomodulating agents from staphylococcus aureus for priming immunotherapy in triple-negative breast cancers. Sci Rep. 2024;14(1):1-16, CrossRef.
Liang X, Mu M, Chen B, Fan R, Chen H, Zou B, et al. Metal-organic framework-based photodynamic combined immunotherapy against the distant development of triple-negative breast cancer. Biomater Res. 2023;27(1):1-18, CrossRef.
Tan H, Liu J, Huang J, Li Y, Xie Q, Dong Y, et al. Ketoglutaric acid can reprogram the immunophenotype of triple-negative breast cancer after radiotherapy and improve the therapeutic effect of anti-PD-L1. J Transl Med. 2023;21(1):1-16, CrossRef.
Chen SF, Ng PL, Lai CW, Wang FJ, Wang YC, Chen MH, et al. Bacterial membrane-modified cerium oxide nanoboosters enhance systemic antitumor effects of radiotherapy in metastatic triple-negative breast cancer. J Nanobiotechnology . 2025;23(1):105, CrossRef.
Yang M, Guo J, Li J, Wang S, Sun Y, Liu Y, et al. Platycodon grandiflorum-derived extracellular vesicles suppress triple-negative breast cancer growth by reversing the immunosuppressive tumor microenvironment and modulating the gut microbiota. J Nanobiotechnology . 2025;23(1):92, CrossRef.
Li K, Wang J, Xie Y, Lu Z, Sun W, Wang K, et al. Reactive oxygen species/glutathione dual sensitive nanoparticles with encapsulation of miR155 and curcumin for synergized cancer immunotherapy. J Nanobiotechnology. 2024;22(1):1-23,
Zhao Y, Bai Y, Li M, Nie X, Meng H, Shosei S, et al. A pH-triggered N-oxide polyzwitterionic nano-drug loaded system for the anti-tumor immunity activation research. J Nanobiotechnology. 2024;22(1):1-18, CrossRef.
Teo ZL, O'Connor MJ, Versaci S, Clarke KA, Brown ER, Percy LW, et al. Combined PARP and WEE1 inhibition triggers anti-tumor immune response in BRCA1/2 wildtype triple-negative breast cancer. npj Breast Cancer. 2023;9(1):1-16, CrossRef.
Huang Y, Qin G, Cui TT, Zhao C, Ren J, Qu X. A bimetallic nanoplatform for STING activation and CRISPR/Cas mediated depletion of the methionine transporter in cancer cells restores anti-tumor immune responses. Nat Commun. 2023;14(1):1-15, CrossRef.
Yan W, Wang S, Zhu L, Yu X, Li J. Targeted editing of CCL5 with CRISPR-Cas9 nanoparticles enhances breast cancer immunotherapy. Apoptosis. 2025;30(3-4):912-35, CrossRef.
Li Y, Chen W, Kang Y, Zhen X, Zhou Z, Liu C, et al. Nanosensitizer-mediated augmentation of sonodynamic therapy efficacy and antitumor immunity. Nat Commun. 2023;14(1):1-17, CrossRef.
Du R, Cao C, Fan D, Li G, Pu S, Xu X, et al. NK cell immunopotentiators-loaded nanoliposomes enhance ADCC effect for targeted therapy against HER2-positive breast cancer. Cell Commun Signal . 2025;23(1):106. , CrossRef.
Zhang X, Liang Q, Cao Y, Yang T, An M, Liu Z, et al. Dual depletion of myeloid-derived suppressor cells and tumor cells with self-assembled gemcitabine-celecoxib nano-twin drug for cancer chemoimmunotherapy. J Nanobiotechnology. 2024;22(1):1-19. , CrossRef.
Tang X, Mao X, Ling P, Yu M, Pan H, Wang J, et al. Glycolysis inhibition induces anti-tumor central memory CD8+T cell differentiation upon combination with microwave ablation therapy. Nat Commun. 2024;15(1):4665, CrossRef.
Foldi J, Blenman KRM, Marczyk M, Gunasekharan V, Polanska A, Gee R, et al. Peripheral blood immune parameters, response, and adverse events after neoadjuvant chemotherapy plus durvalumab in early-stage triple-negative breast cancer. Breast Cancer Res Treat. 2024;208(2):369-77, CrossRef.
Kristeleit R, Leary A, Oaknin A, Redondo A, George A, Chui S, et al. PARP inhibition with rucaparib alone followed by combination with atezolizumab: Phase Ib COUPLET clinical study in advanced gynaecological and triple-negative breast cancers. Br J Cancer. 2024;131(5):820-31, CrossRef.
Yang Z, Hou Y, Grande G, Cho JH, Wang C, Shi Y, et al. Targeted desialylation and cytolysis of tumour cells by fusing a sialidase to a bispecific T-cell engager. Nat Biomed Eng. 2024;8(5):499-512, CrossRef.
Gómez-Aleza C, Nguyen B, Yoldi G, Ciscar M, Barranco A, Hernández-Jiménez E, et al. Inhibition of RANK signaling in breast cancer induces an anti-tumor immune response orchestrated by CD8+ T cells. Nat Commun. 2020;11(1):6335, CrossRef.
DOI: https://doi.org/10.18585/ijbcs.v1i2.26
Refbacks
- There are currently no refbacks.
Copyright (c) 2026 Indonesian Journal of Basic and Clinical Studies
The Prodia Education and Research Institute
